

American Society of Hypertension Symposium Series  
Volume 3

---

# Progress in Atrial Peptide Research

Editors

**Barry M. Brenner, M.D.**

*Director, Renal Division  
Department of Medicine  
Brigham and Women's Hospital  
and Harvard Medical School  
Boston, Massachusetts*

**John H. Laragh, M.D.**

*Director, Cardiovascular Center  
and Department of Medicine  
Cornell University Medical College  
New York, New York*

Raven Press  New York

# Contents

Preface	v
Contributors	xix
Author Index	xxv

## *Chapters*

1 Processing of Atrial Natriuretic Factor Precursors <i>Tadashi Inagami and Teruaki Imada</i>	1
2 Calcium Modulates the Processing of Atriopeptin Prohormone Cleavage in the Isolated Perfused Rat Heart <i>Takayuki Ito, Yukio Toki, and Philip Needleman</i>	13
3 Comparative Study of the Molecular Form of ANP in Human Atrium and Plasma <i>Mitsuhide Naruse, Michiaki Hiroe, Kiyoko Naruse, Makoto Nagata, Zheng-Pei Zeng, Akimasa Hashimoto, Hitoshi Koyanagi, Hiroshi Demura, and Kazuo Shizume</i>	17
4 Structural and Conformational Requirements of ANP Clearance Receptors <i>R.M. Scarborough, M.A. Hsu, L-L. Kang, G.A. McEnroe, K. Schwartz, A. Arfsten, and J.A. Lewicki</i>	23
5 Use of Urinary Cyclic GMP Excretion as a Biologic Marker of the Renal Activity of Atrial Natriuretic Factor <i>Martin G. Cogan, Chou-Long Huang, Fu-Ying Liu, Kenneth R. Wong, Ming-Hong Xie, Lan-Bo Shi, Harlan E. Ives, and David G. Gardner</i>	31
6 A Novel Model Depicting the Protein Kinase C Regulation of Atrial Natriuretic Factor-Dependent 180-kDa Membrane Guanylate Cyclase <i>Rameshwar K. Sharma, Teresa Duda, and Ravi B. Marala</i>	43

7 Atrial Natriuretic Factor and Cyclic AMP Modify Protein Phosphorylation in Renal Papillary Membranes of Dahl Rats 53  
*Alexander Hinko and John P. Rapp*

8 A Physiological Role for Atrial Peptides in Endocrine Control Mechanisms 65  
*David J. Ramsay and Terry N. Thrasher*

9 Effects of Human Atrial Natriuretic Peptide on Renal Function in Conscious Dogs 77  
*Hans-Hellmut Neumayer, Michael Blossei, Ute Seherr-Thohs, and Karl Wagner*

10 Dopamine and Renal Action of Atrial Natriuretic Peptide 89  
*Kiyoshi Kurokawa, Samaisukh Sophasan, and Tetsuo Kato*

11 Regulation of Electrolyte Transport in the Renal Cortical Collecting Duct by Vasopressin and Natriuretic Peptides 95  
*Mark A. Knepper*

12 Reversal of the Hypotensive Effects of Atrial Natriuretic Factor in Anesthetized Rats 111  
*Rodney W. Lappe, Nobert K. Metz, and Robert L. Wendt*

13 Drug Effects and Atrial Natriuretic Peptide in Experimental Cardiac Failure 121  
*C.I. Johnston, M. Kohzuki, P.A. Phillips, and G.P. Hodzman*

14 Plasma ANP in Chronic Renal Failure and Effects of Changes in Dietary Sodium Intake 131  
*S. Spencer, G.A. Sagnella, N.D. Markandu, M.A. Miller, M.G. Buckley, A.L. Sugden, D.R.J. Singer, and G.A. MacGregor*

15 Amelioration of Postischemic Acute Renal Failure in Conscious Dogs by Human Atrial Natriuretic Peptide 141  
*Hans-Hellmut Neumayer, Michael Blossei, Ute Seherr-Thohs, and Karl Wagner*

16 Atrial Natriuretic Peptide in Normal Humans: Hemodynamic and Renal Effects after Single and Repeated Bolus Injection 155

*Gert Müller-Esch, Jürgen Potratz, Michael Kentsch,  
Peter Ball, Rupert Gerzer, Sabine Klohs,  
Rüdiger Lawrenz, and Peter C. Scriba*

<b>17</b>	<b>Clinical Studies with Atrial Natriuretic Peptides</b>	<b>169</b>
	<i>M. Burnier, B. Waeber, J. Biollaz, J. Nussberger, and H.R. Brunner</i>	
<b>18</b>	<b>The Role of Resistance to Atrial Natriuretic Peptide in the Pathogenesis of Sodium Retention in Hepatic Cirrhosis</b>	<b>185</b>
	<i>Leonard C. Warner, Wai-Ming Leung, Peter Campell, Judy Miller, Alexander Logan, Laurence M. Blendis, and Karl L. Skorecki</i>	
<b>19</b>	<b>Atrial Natriuretic Peptide in Patients with Liver Disease</b>	<b>205</b>
	<i>Murray Epstein and Rodger Loutzenhiser</i>	

### *Extended Abstracts*

#### **Section I: ANP Synthesis, Storage, Secretion, and Radioimmunoassays**

Effects of Calcium-free Condition and Hypoxia on ANP Release from Isolated Rat Hearts	213
<i>Yuko Kato, Mitsuhide Naruse, Toshihiko Higashida, Kiyoko Naruse, Zheng- Pei Zeng, Hiroshi Demura, Tadashi Inagami, and Kazuo Shizume</i>	
Immunoenzymatic Assay of C- and N-Terminal Portions of ANF	217
<i>Gaétan Thibault, Philippe Pradelles, Jacques Grassi, and Marc Cantin</i>	
Atrial Natriuretic Peptide in Bovine Plasma and Urine	220
<i>Naoyuki Tkemura, Kenji Ando, Hidekazu Koyama, Toshinori Sako, Tomiya Uchino, Shigekatsu Motoyoshi and Fumiaki Marumo</i>	
Molecular Forms of Immunoreactive ANP in Human Plasma and Urine	223
<i>Kenji Ando, Koji Kihira, Yoichi Katoh, Takashi Masuda, Toshiro Kurosawa, and Fumiaki Marumo</i>	
Infusion of Atrial Natriuretic Peptide in Dogs on Low and High NaCl Diets: Plasma Levels and Disappearance Times	227
<i>D.B. Jennings, I. Sarda, M.S. Douglas, and T.G. Flynn</i>	
Effect of Morphine on Plasma ANP and Other Sodium Dependent Hormones in Normal Men	235
<i>G. Wambach, M. Weber, M. Stimpel, G. Bönner, and W. Kaufmann</i>	

<b>Big ANF in Rabbit Plasma</b> <i>Nadine Wilson, Ralph Keeler, John R. Ledsome, Andrew Wong, and Veronica Yakoleff</i>	239
<b>Identification and Characterization of Immunoreactive ANP-like Material in Guinea Pig Intestine</b> <i>A.M. Vollmar, A. Friedrich, and R. Schulz</i>	241
<b>Regulation of Plasma ANF Concentration in the Sheep Fetus</b> <i>Cecilia Y. Cheung and Robert A. Brace</i>	244
<b>Atrial Natriuretic Polypeptide-like Immunoreactive Substances (ANP-IR) in Fish Hearts</b> <i>Z.H. Shao, C.Q. Li, L.Y. Zhang, J.K. Liu, S.S. Zhang, and S.Y. Dong</i>	247
<b>Immunoreactive ANF and ANF Binding Site in Rat Olfactory Mucosa: Effect of Nasal Application of ANF on Urinary Secretion</b> <i>J. Gutkowska, M. Marcinkiewicz, and L. Pan</i>	252
<b>Section II: ANP Receptors and Second Messengers</b>	
<b>Tissue-specific Heterogeneity of the Atrial Natriuretic Factor Receptors</b> <i>Kailash N. Pandey and Tadashi Inagami</i>	255
<b>Atrial Natriuretic Peptide Receptors are Increased in Supraoptic and Paraventricular Nuclei of Brattleboro Rats</b> <i>Eero Castrén and Juan M. Saavedra</i>	260
<b>Atrial Natriuretic Peptides in the Brain of Rats with Inherited Diabetes Insipidus (Brattleboro Rats)</b> <i>Udo Bahner, Helmut Geiger, Miklos Palkovits, Detlev Ganter, Joachim Michel, Mariann Fodor, and August Heidland</i>	264
<b>Atrial Natriuretic Factor Binding Sites in the Jejunum</b> <i>Césario Bianchi, Edyta Wrobel-Konrad, Gaétan Thibault, André De Léan, Marie-Claude Grenier, Jacques Genest, and Marc Cantin</i>	269
<b>Down Regulation of ANF Receptors by Phorbol Dibutyrate in Cultured Vascular Smooth Muscle Cells</b> <i>Pierre Roubert, Pierre-Etienne Chabrier, Pascale Plas, and Pierre Braquet</i>	273
<b>Renal Structure - Activity Relationships of Ring-Deletion Analogs of Atrial Natriuretic Factor</b> <i>Rodney W. Lappe, Charlotte M. Harvey, Robert L. Wendt, John A. Lewicki, Glen A. McEnroe, and Robert M. Scarborough</i>	276
<b>Potentiation and Inhibition of ANF Activity by its Analogs</b> <i>R. Willenbrock, M. Heim, P.W. Schiller, J. Tremblay, and P. Hamet</i>	279
<b>Glomerular and Vascular Atrial Natriuretic Factor Receptors in Adrenalectomized Rats: Correlation with the Peptide's Biological Effects</b> <i>Victoria Cachofeiro, Marc Cantin, Ernesto L. Schiffrin, and Raul Garcia</i>	283
<b>Effect of Chelators on the Binding of Atrial Natriuretic Factor to Human Placental Membranes: Identification of Multiple Forms of Atrial Natriuretic Factor Receptor</b> <i>Ulhas Naik, Pampa Roy, and Indira Sen</i>	287

Atrial Natriuretic Factor Negatively Regulates Autophosphorylation of Protein Kinase C in Plasma Membranes of Murine Leydig Tumor Cells and Bovine Adrenal Cortical Cells <i>Kailash N. Pandey and Tadashi Inagami</i>	290
The Sensitivity of Particulate Guanylate Cyclase to Atrial Natriuretic Factor is Increased by Amiloride and Triton X-100 <i>Krassimira Ivanova, Jörg-Martin Heim, Barbara Lückenga, and Rupert Gerzer</i>	294
Characterization of ANF-Induced Inhibition of Adenylate Cyclase <i>Madhu B. Anand-Srivastava and Marc Cantin</i>	297
Atrial Natriuretic Factor (ANF) Receptors are Coupled to Adenylate Cyclase in Rat Platelet Membranes <i>Madhu B. Anand-Srivastava, J. Gutkowska, and M. Cantin</i>	301
8-Br-cGMP Versus ANP in Conscious Dogs: Hemodynamic, Renal and Hormonal Effects <i>Dietmar Elsner, Eckhard P. Kromer, and Günter A.J. Rieger</i>	305
Inhibition of ANF Vasorelaxation by EIPA: A Role for $\text{Na}^+/\text{H}^+$ Exchange? <i>Sandeep Gupta, Edward J. Cragoe, Jr., and Richard C. Deth</i>	309
<b>Section III: ANP and the Endocrine and Nervous Systems</b>	
Arginine Vasopressin (AVP)-enhanced Release of $\alpha$ -Atrial Natriuretic Factor From Unstretched Rat Atria Incubated In Vitro <i>G.A. Zeballos, C. Hoegler, M.H. Gewitz, and J.M. Stewart</i>	315
Does Atrial Natriuretic Factor Inhibits Activation of Prorenin to Plasma Renin in Conscious Dogs? <i>D.H. Osmond, C.T. Thompson, M.S. Douglas, and D.B. Jennings</i>	318
Atrial Natriuretic Factor Inhibits Isoproterenol and Furosemide-stimulated Renin Release in Humans <i>John J McMurray and Allan D Struthers</i>	328
Involvement of Atrial Natriuretic Peptide of the Brain AV <sub>3</sub> V Region in the Water and Salt Homeostasis <i>Helmut Geiger, Udo Bahner, Miklos Palkovits, Christian Hugo, Elisabeth Niklas, and August Heidland</i>	333
Atrial Natriuretic Factor Constitutes an Intrinsic Functional Unit in Sympathetic Ganglia <i>W. Debinski, O. Kuchel, N.T. Buu, J. Tremblay, and P. Hamet</i>	338
Atrial Natriuretic Factor Inhibits Adrenergic Neurotransmission in Rabbit Isolated Portal Veins <i>James G. Drewett, Gary R. Marchand, and George J. Trachte</i>	342
Inhibitory Action of Atrial Natriuretic Polypeptide and Other Vasoactive Neuropeptides on Neurotransmitter Release in Hypertension <i>Kazushi Tsuda, Seiko Tsuda, and Yoshiaki Masuyama</i>	351
Is a Hypophyseal Factor Required for Atrial Natriuretic Factor Secretion? <i>Aaron Hoffman and Harry R. Keiser</i>	356

The Role of Endogenous ANP in DOCA Salt Hypertension <i>C. Hirth, S. Kazda, A. Knorr, J.-P. Stasch, and S. Wohlfel</i>	359
Interaction Between Atrial Peptides and Endogenous Digitalis during the Development of Mineralocorticoid Hypertension: A New Axis? <i>John M. Hamlyn</i>	363
Physiological Doses of Atrial Peptide Inhibit Angiotensin II-stimulated Aldosterone Secretion in Conscious Dogs <i>Craig H. Metzler and David J. Ramsay</i>	368
Hormonal Effects of Alpha-Human Natriuretic Peptide in Patients with Primary Aldosteronism <i>Saleh Abdelhamid, Paul Vecsei, Roland Blomer, Michael Jansky, Arnold Röckel, Dieter Walb, and Peter Fiegel</i>	371
Modulation of Na/K-ATPase Activity by Ouabain and Growth Hormone: Effects on Circulating Atrial Natriuretic Peptides <i>K. Peter Ohman, Margaret Slover, Harry R. Keiser, and Nadav Zamir</i>	384
Renal Action of Human Atrial Natriuretic Peptide in Active Acromegaly <i>Eckart Jungmann, Undine Schirmer, Ernst-H. Scheuermann, Stefan Zeuzem, and Karl Schöffling</i>	388
Naloxone Does Not Antagonize the Clonidine-induced Increase In Plasma Atrial Natriuretic Peptides in Rats <i>Nadav Zamir, Margaret Slover, Harry Keiser, Irwin Kopin, and Peter Ohman</i>	392
Effects of STZ-induced Diabetes on Atrial Natriuretic Peptide Levels in Rats <i>Leslie Seale Black and John C. Lee</i>	396
Plasma Volume and Atrial Natriuretic Peptide Concentration during Pregnancy and Postpartum in Rats <i>Alan L.A. Boura, Chaweewan Jansakul, Roger G. King, Shaun P. Brennecke, and Gwynneth M. Handberg</i>	400
Atrial Natriuretic Peptide in the Puerperium as Compared with Pregnancy in Healthy Women: Increased Plasma Concentrations Postpartum Possibly Participating in the Stimulation of Natriuresis Immediately after Delivery <i>Lorenzo S. Malatino, Benedetta Stancanelli, Giuseppe Greco, Luisa Gitto, Giuseppe Ettore, Paolo Scollo, and Giacomo Tamburino</i>	403
Thyroid Hormone and Glucocorticoid Modulate the Release of Atrial Natriuretic Peptides from Cardiac Atria <i>Nadav Zamir, Markus Haass, Margaret Slover, and Peter Ohman</i>	407
ANF Involvement in the Diuresis of Hyperthyroidism <i>Donald F. Sellitti, Phillip A. Passarelli, and Keith R. Latham</i>	412
Relationships between Atrial Natriuretic Peptides and Amphetamine in Idiopathic (Orthostatic) Edema <i>John J. Canary, Sam J. Bhathena, Patricia M. Smith, Myra L. Glen, Carol A. Gannon, and Bruce W. Kennedy</i>	416
Lack of Inhibiting Effect of Human Atrial Natriuretic Peptide on Pituitary and Adrenal Hormone Stimulation during Insulin-induced Hypoglycemia <i>Eckart Jungmann, Thomas Haak, Christine Konzok, Edmond Höll, and Karl Schöffling</i>	420

Raised ANF Concentrations in Normotensive Obese Patients: Discrepancy between Radioreceptor and Radioimmunoassay Measurements <i>L. Heinemann, P.T. Sawicki, A. Hohmann, K. Rave, W. Mensel, and M. Berger</i>	423
Plasma Atrial Natriuretic Peptide Concentration (p-ANP-c) during Licorice Ingestion in Healthy Volunteers <i>Terje Forsslund, Frej Fyhrquist, Bertil Frøseth and Ilkka Tikkanen</i>	426
ANP and Other Fluid-Regulating Hormones during Space Flight <i>N.M. Cintrón, C.S. Leach, J.M. Krauhs, and J.B. Charles</i>	431
Atrial Natriuretic Factor in Fetal Alcohol Syndrome in Rats <i>Lawrence M. Dolan, Carolyn A. Young, and Charles V. Vorhees</i>	435
Atrial Natriuretic Factor in Chronic Hypoxic Pulmonary Hypertension: Physiological Correlates and Responses to Peptide Infusion <i>Serge Adnot, Pierre Andrivet, Pierre-Etienne Chabrier, Jacques Piquet, Pierre Braquet, and Christian Brun-Buisson</i>	438

#### Section IV: ANP in Heart Disease and Hypertension

Atrial Natriuretic Factor Release during Angiotensin II Infusion in Right and Left Atrial Appendectomized Rats <i>Danielle Lachance and Raul Garcia</i>	441
Plasma Atrial Natriuretic Peptide Level and Molecular Forms in Dogs with Acute Heart Failure Induced by Experimental Aortic Regurgitation <i>Takashi Masuda, Kiyotaka Satoh, Yoshihiko Masaki, Kenji Ando, and Fumiaki Marumo</i>	445
Plasma Atrial Natriuretic Peptide Level and Molecular Forms in Dogs with Acute Heart Failure Induced by Experimental Mitral Regurgitation <i>Kiyotaka Satoh, Takashi Masuda, Yoshihiko Masaki, Kenji Ando, Nobuhiro Hasegawa, Ryuichi Kikawada, and Fumiaki Marumo</i>	447
Natriuretic and Urinary Cyclic Guanosine Monophosphate Responses to Infused Atrial Natriuretic Peptide in Rats with Chronic Myocardial Infarction <i>Masahiro Kohzuki, G. Peter Hodsman, and Colin I. Johnston</i>	449
<i>In Vivo and In Vitro Effects of Atrial Natriuretic Factor on Renal Cyclic GMP Production in Rats with Experimental Heart Failure</i> <i>Joseph Winaver, Zaid Abassi, Aaron Hoffman, Ori S. Better, and Aviad Haramati</i>	453
Attenuated Diuretic and Natriuretic Effect of Atrial Natriuretic Peptide in Rats with Heart Failure <i>Ilkka Tikkanen, Tuula Tikkanen, Hannu Sariola, Margareta Svarström-Fraser, and Frej Fyhrquist</i>	458
Renal and Adrenal Resistance against Exogenous ANP in Congestive Heart Failure: Effect of Enalapril <i>G. Wambach, U. Schittenhelm, S. Degenhardt, G. Bönner, and W. Kaufmann</i>	461

Effects of Atrial Natriuretic Peptide on Voltage-dependent Inactivation of T-Type Calcium Channel Current <i>Richard T. McCarthy, Carlos M. Isales, and Paula Q. Barrett</i>	464
Limited Role of Right Atrial Pressure in the Acute Control of Circulating Atrial Natriuretic Factors. Volume Expansion and Lower Body Negative Pressure in Young and Aged Healthy Men <i>Hermann Saxenhofer, Christoph Cottier, Susanne Suda, Sidney Shaw, Claudia Ferrier, and Peter Weidmann</i>	468
Evidence for the Sidedness in the Baroreceptorial Regulation of Atrial Natriuretic Peptide in Normal Human Subjects <i>Anna Santucci, Vincenzo Marigliano, Ilio Cammarella, Claudio Ferri, Riccardo Leonetti Luperini, Claudio De Angelis, Antonio Musca, and Francesco Balsano</i>	476
Plasma Levels of Atrial Natriuretic Peptide and its Correlates in a Male Working Population <i>Francesco P. Cappuccio, Graham A. MacGregor, Pasquale Strazzullo, Giuseppe A. Sagnella, Licia Iacoviello, Martin G. Buckley, Eduardo Farinaro, and Mario Mancini</i>	480
Increased Atrial Natriuretic Peptide and Decreased Vasopressin during Supraventricular Tachycardia <i>Mitsuhide Naruse, Satoshi Ohnishi, Kiyoko Naruse, Hiroshi Kasanuki, Tamotsu Shibasaki, Hiroshi Demura, Koshichiro Hirosawa, Tadashi Inagami, and Kazuo Shizume</i>	483
Role of Right Atrial Wall Stress in ANP Release in Patients with Heart Disease <i>Thomas A. Fischer, Markus Haass, Rudolf E. Lang, and Rainer Dietz</i>	492
Does the Determination of Atrial Natriuretic Peptide Replace Diagnostic Right Heart Catheterization during Treadmill Exercise? <i>T. Eisenhauer, J. Talartschik, K.-H. Scholz, and K.L. Neuhaus</i>	496
Change of Molecular Forms of Atrial Natriuretic Peptide in Treated Congestive Heart Failure <i>T. Kurosawa, S. Takeda, N. Hasegawa, K. Ando, R. Kikawada, and F. Marumo</i>	501
Atrial Natriuretic Peptide in Patients with Acute Cerebroocclusion and Heart Failure <i>C.Q. Li, Z.H. Shao, S.Y. Liu, C.X. Zhao, Q.Y. He, and L.Y. Zhang</i>	503
Plasma ANP Changes in Patients with Heart Failure and Cerebroocclusion Treated with Isometric Dilution Therapy <i>C.Q. Li, Z.H. Shao, S.Y. Liu, C.X. Zhao, Q.Y. He, and L.Y. Zhang</i>	509
Persistent Elevation of ANP and Cyclic GMP Concentrations in Plasma of Patients after Cardiac Surgery <i>Klaus P. Kohse, Klaus Hellberg, and Herrmann Wisser</i>	511
Plasma Levels of Atrial Natriuretic Peptide in Cardiac Transplant Recipients during Dynamic Exercise <i>Dietmar H. Petzl, Engelbert Hartter, Gregor Wollenek, Wolfgang Schuller, Wolfgang Woloszczuk, Christian Wolf, Werner Scheithauer, and Oswald Jahn</i>	515

Peripheral Vascular Effects of Atrial Natriuretic Peptide after Total Artificial Heart Implantation <i>Timothy E. Oaks, James A. Magovern, Walter E. Pae, and William S. Pierce</i>	519
Atrial Natriuretic Peptide and Atrial Pressure in Calves with Total Artificial Hearts <i>James A. Magovern, Walter E. Pae, Jr., Timothy E. Oaks, William S. Pierce, John A. Waldhausen, and Roscoe E. Hersey</i>	523
Plasma Atrial Natriuretic Factor during the Week after Orthotopic Heart Transplantation <i>D. Farge, R. Guillemain, D. Payen, C. Amrein, G. Dreyfus, I. Viossat, P.E. Chabrier, and P. Braquet</i>	525
Atrial Natriuretic Peptide Prevents Hypoxia-induced Pulmonary Hypertension in Rats <i>Ren-Hui Yang, Hongkui Jin, Yiu-Fai Chen, Robert M. Jackson, and Suzanne Oparil</i>	529
Silicosis and Atrial Natriuretic Polypeptides <i>Z.H. Shao, C.Q. Li, L.Y. Zhang, Y.L. Jing, Y.M. Cheng, J.K. Liu, S.Y. Dong, and S.S. Zhang</i>	533
Free and Bound Forms of Atrial Natriuretic Peptide in Rat Plasma: A Comparison of Spontaneously Hypertensive Rats and Wistar Kyoto Rats <i>Johji Kato, Osamu Kida, Toshihiro Kita, Shigeru Nakamura, Akira Sasaki, Kenji Kodama, and Kenjiro Tanaka</i>	541
Central Atrial Natriuretic Peptides in Young (Prehypertensive) Spontaneously Hypertensive Rats <i>Udo Bahner, Helmut Geiger, Miklós Palkovits, Csilla Pammer, Klaus Schafferhans, and August Heidland</i>	545
Regulation of Brain Atrial Natriuretic Peptide Binding Sites in Spontaneously Hypertensive Rats after Chronic Antihypertensive Treatment with Enalapril <i>A.J. Nazarali, J.S. Gutkind, F.M. Correa, and J.M. Saavedra</i>	549
The Distribution, Origin and Possible Role of Neural ANF in Spontaneously Hypertensive Rats <i>Otto Kuchel, Waldemar Debinski, Gaétan Thibault, Marc Cantin, and Jacques Genest</i>	554
Glomerular Atrial Natriuretic Factor Receptors in Spontaneously Hypertensive Rats <i>Raul Garcia, Guillemette Gauquelin, Gaétan Thibault, Marc Cantin, and Ernesto L. Schiffrin</i>	557
Atrial Natriuretic Factor Attenuates Hypertension Induced by Acute Unilateral Renal Artery Clipping in Rats <i>Massimo Volpe, R. Ernest Sosa, Steven A. Atlas, Maria J. Camargo, Carla Sala, Franco B. Muller, E. Darracott Vaughan, Jr., and John H. Laragh</i>	561
Vascular Receptors for Atrial Natriuretic Peptide in Spontaneously Hypertensive Rats <i>Ernesto L. Schiffrin, Jean St-Louis, Pavel Hamet, and Raul Garcia</i>	564

Important Role of Brain ANP in the Development of DOCA-Salt Hypertension in Rats <i>Helmut Geiger, Udo Bahner, Miklos Palkovits, Jürgen Hupe, Klaus Schafferhans, and August Heidland</i>	567
Mechanism Mediating the Hypotensive Effect of Atrial Natriuretic Factor in Sodium-depleted Dogs: Role of Renin Suppression <i>Joey P. Granger, Elizabeth Meadows, Soheil Sooudi, and D. Lowell Stacy</i>	572
Influence of Acute Venodilation by Captopril on the ANP and Pressor Modifications in Borderline Hypertension <i>C. Borghi, S. Boschi, A. Mussi, F.V. Costa, and E. Ambrosioni</i>	575
Influence of DA <sub>2</sub> Receptor Blockade on Plasma ANF and on Its Humoral and Renal Effects in Human Hypertensives <i>A.R. Lucarini, P. Arrighi, S. Favilla, N. Simonini, and A. Salvetti</i>	580
No Changes in Plasma Insulin and Cortisol during ANF Infusions in Essential Hypertension <i>Giancarlo Tonolo, Paolo Manunta, A. Mark Richards, Aldo Soro, Mario Maioli, and Nicola Glorioso</i>	584

#### Section V: ANP Effects on the Kidney and Liver

Atrial Natriuretic Peptide Reverses Norepinephrine-induced Afferent Arteriolar Vasoconstriction <i>Roger Loutzenhiser, Koichi Hayashi, and Murray Epstein</i>	589
Vasopressin and Norepinephrine Potentiate the Renal Effects of Synthetic Atrial Natriuretic Factor in a Model of Experimental Cirrhosis <i>Daniel R. Ganger, Jeanne Gottstein, and Andres T. Blei</i>	598
Norepinephrine Attenuates the Renal Effects of Atrial Natriuretic Factor in Men <i>John J. McMurray, Peter H. Seidelin, and Allan D. Struthers</i>	602
Arginine Vasopressin Dissociates the Natriuresis and Diuresis Due to Atrial Natriuretic Factor in Men <i>John J. McMurray and Allan D. Struthers</i>	606
Clinical Studies on the Effects of Atrial Natriuretic Peptide on Antidiuretic Hormone and Urinary Dilution <i>Yasunobu Hirata, Masao Ishii, Kazushige Fukui, Tokuichiro Sugimoto, Hiroaki Matsuoka, Tsuneaki Sugimoto, Kenji Kangawa, and Hisayuki Matsu</i>	610
Effect of Atrial Natriuretic Peptide on Renal Sodium Handling in Unilaterally Kidney-denervated Rats <i>Wladimiro Jiménez and Daniel C. Batlle</i>	614
Hemodynamic Responses to Atrial Natriuretic Factor in Nephrectomized Rabbits <i>Massimo Volpe, Filippo Vecchione, Giuseppe Lembo, Alberto Cuocolo, Silvana Pignalosa, GianLuigi Condorelli, and Bruno Trimarco</i>	618

Atrial Natriuretic Factor Release in Diabetic Uremic Patients with Severe Combined Sympathetic Parasympathetic Dysfunction <i>Carmine Zoccali, Francesca Mallamaci, Maurizio Cincarelli, Filippa Salnitro, Saverio Parlongo, and Adalgisa Curatola</i>	621
Changes in the Molecular Forms of Atrial Natriuretic Peptide by a Single Hemodialysis <i>Fumiaki Marumo, Atsushi Yoshida, Akira Kurokawa, Miyoko Kamiyama, and Kenji Ando</i>	625
Prevention of Uranyl Nitrate-induced Acute Renal Failure by Renal Denervation and Atrial Natriuretic Peptide: A Comparative Study <i>K. Schafferhans, H. Geiger, R. Herzog, and A. Heidland</i>	627
Additive Protective Action of Atrial Natriuretic Peptide and Verapamil in Gentamicin-induced Acute Renal Failure <i>K. Schafferhans, U. Bahner, R. Schmatz, and A. Heidland</i>	632
Atrial Natriuretic Peptide Reverses Experimental Acute Renal Failure Induced by Arginin Vasopressin <i>Ekkehart Heidbreder, Klaus Schafferhans, Thomas Zollner, Rüdiger Götz, and August Heidland</i>	636
Excretion Patterns for Inulin and Sodium in Rat Kidneys: Effect of Atrial Natriuretic Peptide on Papillary Necrosis <i>Ralph Keeler and Ana Maria Azzarolo</i>	640
Atrial Natriuretic Factor Increases Urinary Albumin Excretion in Men <i>John J. McMurray, Peter H. Seidelin, Jaquie Howey, and Allan D. Struthers</i>	643
Effects of the Calcium Channel Blocker Nifedipine on ANP Secretion and Renal Excretory Function During Head-Out Water Immersion <i>H. Meyer-Lehnert, C. Till, H.G. Predel, and H.J. Kramer</i>	647
ANF and Renal Excretory Functions Related to Changes in Intrathoracic Pressure <i>Pierre Andrivet, Serge Adnot, Pierre-Etienne Chabrier, Pierre Braquet, and Christian Brun-Buisson</i>	650
Effect of Auriculin on the Salt Gland of the Duck <i>Herbert G. Langford and Katie Holder</i>	653
Atrial Natriuretic Factor in Ascites of Patients with Cirrhosis of the Liver or with Malignant Neoplasms <i>Alexander L. Gerbes, Angelika M. Vollmar, Yining Xie, and Rainer M. Arendt</i>	656
Subject Index	661

## CHAPTER 16

# Atrial Natriuretic Peptide in Normal Humans: Hemodynamic and Renal Effects after Single and Repeated Bolus Injection

\*Gert Müller-Esch, \*Jürgen Potratz, \*Michael Kentsch,  
\*\*Peter Ball, †Rupert Gerzer, \*Sabine Klohs,  
\*Rüdiger Lawrenz, and \*Peter C. Scriba

*Departments of \*Medicine and \*\*Biochemical Endocrinology, Medical University Lübeck, and †Department of Medicine, University München, Federal Republic of Germany*

To study cardiovascular and diuretic effects and to establish whether there is an attenuation of response after repeated application, we gave a single or two 30-min-apart bolus injections of 200 µg human atrial natriuretic peptide ( $\alpha$ -hANP). Before and after  $\alpha$ -hANP bolus injections, echocardiography was performed and plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) as well as urinary cGMP excretion were determined. Plasma cGMP rose from basal  $3.4 \pm 1.1$  to  $25.0 \pm 6.7$  nmol/liter within 10 min after the first injection and from  $20.0 \pm 6.0$  before the second administration to  $32.7 \pm 11.1$  nmol/liter another 10 min later. Urine volume (30-min sampling periods) increased from  $2.1 \pm 2.5$  to  $16.1 \pm 5.3$  after the first and to  $22.6 \pm 7.0$  ml/min after the second bolus. Urine sodium excretion increased from  $6.2 \pm 2.9$  to  $43.0 \pm 18.5$  and  $38.7 \pm 21.0$  mmol/hr. After each  $\alpha$ -hANP bolus, there was a significant decrease in mean arterial blood pressure and increase in heart rate. The ejection fraction increased from  $66.2 \pm 3.7$  to  $76.4 \pm 4.0\%$  after the first bolus and from  $66.8 \pm 3.8$  before the second to  $76.9 \pm 5.0$  after the second  $\alpha$ -hANP bolus. All reported changes are significant ( $p < 0.01$ ).

Single and repeated bolus applications of 200 µg of  $\alpha$ -hANP in healthy volunteers increases plasma and urinary cGMP, diuresis, and natriuresis as well as echocardiographically determined ejection fraction and decreases arterial blood pressure. Reproducible diuretic effects and improved cardiac performance after repeated bolus application of  $\alpha$ -hANP may be beneficial in the treatment of congestive heart failure.

$\alpha$ -hANP is a cardiac hormone with diuretic, natriuretic, and vasodilating properties (1-3). When given either as a bolus or as an infusion intravenously in normal humans,  $\alpha$ -hANP causes a rise in urinary volume and sodium excretion (1,2). The hemodynamic actions of  $\alpha$ -hANP are yet not well defined. After an  $\alpha$ -hANP bolus, Richards et al. observed an increase of heart rate and a decrease of blood pressure (1). During infusion of  $\alpha$ -hANP, Cuneo et al. could not detect changes of heart rate or blood pressure (4), but Indolfi et al. reported decreased blood pressure while the heart rate was kept constant by cardiac pacing (5). Vasodilating actions (4) as well as other hemodynamic and diuretic effects of  $\alpha$ -hANP depend on the application scheme and the given dose (6).

In this study, our aim was to investigate the effects of single and repeated high dose  $\alpha$ -hANP bolus injections in normal humans on (a) cGMP response, (b) hemodynamic parameters detectable by echocardiography, and (c) diuresis and natriuresis.

## MATERIALS AND METHODS

The first part of the study (protocol 1) was performed in seven healthy volunteers (six men and one woman;  $27.7 \pm 1.8$  years) without any evidence of heart disease. After an overnight fast and bed rest,  $200 \mu\text{g}$  of  $\alpha$ -hANP (Bissendorf Peptide, Wedemark, FRG) were given as a bolus injection intravenously.

Heart rate and blood pressure were monitored noninvasively by an automatic device (Dynamap<sup>R</sup>). M-mode echocardiography was performed 40 and 20 min before as well as 5, 10, 15, 30, 45, 60, 120, and 180 min after the injection of  $\alpha$ -hANP.

Venous blood samples were drawn for the determination of ANP, cGMP, hematocrit, sodium, potassium, and serum osmolality at  $-20, \pm 0, +2, +5, +10, +20, +35, +60, +90$ , and  $+180$  min. Urine was collected at 30-minute intervals for measuring the excretion of sodium, potassium, and cGMP. Urine output was replaced throughout the study by oral water.

Informed consent was given; the study was approved by a local ethics committee.

### Echocardiography

An IREX III (m-mode) echocardiograph together with a CARDIO 200 computer for the elaboration of the data was used. The left ventricular dimensions were obtained when the ultrasonic beam was directed at the chamber between the mitral valve echos and the papillary muscle echos (7). The end-diastolic diameter (EDD) was taken at the peak of the R-wave and from the trailing edge of the left side of the intraventricular septum to the leading edge of the posterior endocardial echo. The end-systolic diameter (ESD)

was taken at the peak downward motion of the intraventricular septum. Ventricular volumes—end-diastolic volume (EDV) and end-systolic volume (ESV), stroke volume (SV), and cardiac index (CI)—were obtained utilizing the formula of Teicholz et al. (8). The ejection fraction (EF) was calculated according to the method of Quinones et al. (9).

### Analytical Methods

ANP (without prior extraction; IBL, Hamburg, FRG) and cGMP (10) were measured by radioimmunoassay.

### Calculation and Statistics

Data are given as means  $\pm$  standard deviation (SD). For statistical analysis, Student's *t*-test for paired data and the analysis of variance for repeated measures over time (11) were used.

In the second part of the study (protocol 2), 200  $\mu$ g of  $\alpha$ -hANP were given twice as intravenous boluses at a 30-minute interval in six healthy volunteers (five men, one woman;  $27.5 \pm 2.4$  years). Again, echocardiography was performed 40 and 20 min before the first administration as well as 5, 10, 15, and 30 min after each bolus and finally at 90, 120, and 180 min. As before, venous blood samples were drawn ( $-40$ ,  $-20$ ,  $\pm 0$ ,  $+2$ ,  $+5$ ,  $+10$ ,  $+20$ ,  $+32$ ,  $+35$ ,  $+40$ ,  $+50$ ,  $+60$ ,  $+90$ ,  $+120$ ,  $+150$ ,  $+180$  min) and urine was collected at 30-minute intervals.

## RESULTS

Within 2 min after each injection, a transient heart rate increase together with a fall of mean arterial pressure occurred (Tables 1 and 2). These

TABLE 1. Hemodynamic, echocardiographic, and laboratory findings after a single bolus injection of  $\alpha$ -hANP<sup>a</sup>

	Basal	Max/min	Time (min)
Heart rate ( $\text{min}^{-1}$ )	$58.6 \pm 4.67$	$79.1 \pm 7.4$	+4
Mean arterial pressure (mm Hg)	$91.3 \pm 5.7$	$81.7 \pm 6.4$	+2
Stroke volume (ml)	$77.5 \pm 15.1$	$90.3 \pm 10.2$	+10
Cardiac index (liters/min/m $^2$ )	$2.44 \pm 0.41$	$2.88 \pm 0.41$	+10
Urinary cGMP (nmol/min)	$0.71 \pm 0.25$	$5.56 \pm 1.94$	0-30
Hematocrit (%)	$41.7 \pm 3.3$	$44.8 \pm 3.2$	+35

<sup>a</sup>Time: time of maximal deviation from baseline values. The significance of all differences between basal and maximal or minimal values (max/min):  $p < 0.01$ .

TABLE 2. *Hemodynamic, echocardiographic, and laboratory findings after repeated bolus injections of  $\alpha$ -hANP\**

	Basal	Max/min	Time (min)
Heart rate ( $\text{min}^{-1}$ )	A $65.5 \pm 8.6$ B $60.2 \pm 7.9$	$79.5 \pm 6.4$ $83.3 \pm 6.7$	+3 +3
Mean arterial pressure (mm Hg)	A $90.0 \pm 3.9$ B $89.8 \pm 5.8$	$82.5 \pm 6.4$ $81.2 \pm 5.3$	+4 +2
Stroke volume (ml)	A $83.4 \pm 11.0$ B $78.6 \pm 13.1$	$95.8 \pm 13.0$ $90.2 \pm 23.7$	+10 +15
Cardiac index (liters/min/m $^2$ )	A $2.97 \pm 0.51$ B $2.63 \pm 0.46$	$3.20 \pm 0.67$ $3.28 \pm 0.93$	+10 +15
Urinary cGMP (nmol/min)	$0.62 \pm 0.42$	$5.68 \pm 1.75$	30–60
Hematocrit (%)	$42.5 \pm 2.5$	$46.7 \pm 2.3$	+40

\*A: first  $\alpha$ -hANP bolus; B: second  $\alpha$ -hANP bolus. Time: time of maximal deviation from baseline values. The significance of all differences between basal and maximal or minimal values (max/min):  $p < 0.01$ .

changes had disappeared another 5 min later. All subjects experienced mild to moderate facial flushing; no severe side effects were observed.

### Hemodynamic Findings

In general, echocardiographic changes were most pronounced 10 to 15 min after the injection of  $\alpha$ -hANP and reached baseline values another 15 to 20 min later.

#### *Single Bolus (Protocol 1)*

The results are given in Figs. 1 and 2 and in Table 1. ESD decreased markedly. As EDD (basal,  $5.06 \pm 0.37$  cm) remained constant, this resulted in an increase of the calculated EF. Correspondingly, SV and CI were augmented by about 17%.

#### *Repeated Bolus Injection (Protocol 2)*

Figures 3 and 4 and Table 2 give the results. Again, ESD decreased significantly while EDD remained unchanged, leading to an increase of calculated EF, SV, and CI. Two-way analysis of variance did not disclose differences between the effects of a single ANP bolus (protocol 1) and the first of two bolus injections (protocol 2). Repeated injection after 30 min provoked comparable hemodynamic responses; an attenuation or waning effect could not be demonstrated.




FIG. 1. End-systolic diameter (ESD) after a single bolus injection of 200 µg of  $\alpha$ -hANP in volunteers; \* $p < 0.01$ .





FIG. 2. Ejection fraction (EF) after single bolus injection of 200 µg of  $\alpha$ -hANP in volunteers; \* $p < 0.01$ .



**FIG. 3.** End-systolic diameter (ESD) and end-diastolic diameter (EDD) after repeated bolus injections of 200 µg of  $\alpha$ -hANP at a 30-min interval;  $*p < 0.01$ .




FIG. 4. Ejection fraction (EF) after repeated bolus injections of 200  $\mu$ g of  $\alpha$ -hANP at a 30-minute interval; \* $p < 0.01$ .


### Renal Findings

#### Single Bolus

Within the first 30 min after injection, urinary volume increased ninefold and sodium excretion increased fivefold (Fig. 5), whereas potassium excretion only doubled. Enhanced diuresis and natriuresis were still present at least 60 min later.

#### Repeated Bolus Injections

Again, the first injection of 200  $\mu$ g of  $\alpha$ -hANP produced clear-cut diuresis and natriuresis together with a moderate increase of potassium excretion. These effects were not different from those in protocol 1. Repeated injection



**FIG. 5.** Urinary volume (U) and urinary sodium excretion (Na<sup>+</sup>) after a single bolus injection of 200 µg of  $\alpha$ -hANP in volunteers; \* $p < 0.01$ .

of  $\alpha$ -hANP evoked prolonged renal actions when compared to single bolus application (Fig. 6; Table 2).

### cGMP

There was a marked rise of plasma cGMP in protocol 1, maximal values being observed between 10 and 20 minutes after injection (Fig. 7). Correspondingly, urinary cGMP excretion increased nearly eightfold during the second collection period (0 to 30 min) (Table 1).

The second  $\alpha$ -hANP bolus resulted in a further increase of plasma cGMP (Fig. 8) together with a more pronounced and persisting cGMP excretion up to the third collection period (30 to 60 minutes) (Table 2). During protocol 2, urinary excretion rose from a basal value of  $0.62 \pm 0.42$  to  $4.70 \pm 1.99$  mmol/min after the first bolus and to  $5.68 \pm 1.75$  mmol/min after the second bolus.

### Other Findings

ANP (basal value,  $195 \pm 94$  pg/ml) rose nearly 15-fold after each injection and had nearly normalized 30 min later. After a single bolus injection, the




FIG. 6. Urinary volume and urinary sodium and potassium excretion after repeated bolus injections of 200 µg of  $\alpha$ -hANP at a 30-min interval; \* $p$  < 0.01.


venous hematocrit had risen after half an hour by 7% and not yet returned to a basal value by the end of the study. Repeated injection produced a slightly greater rise of 10% (Tables 1 and 2). Serum concentrations of sodium and potassium remained unchanged during both protocols. Apart from a moderate, symptomatic flush, no side effects were observed in the healthy volunteers.

## DISCUSSION

The data demonstrate reproducible transient increases of heart rate and a reduction of blood pressure after single and repeated bolus injections of 200 µg of  $\alpha$ -hANP. These results correspond well with previous observations after a single bolus of 100 µg of  $\alpha$ -hANP (1).

Intravenous ANP in humans produces an increase of plasma cGMP and of urinary cGMP excretion (10). Probably because of the higher  $\alpha$ -hANP bolus dose of 200 µg in the present study, the plasma and urinary response was more pronounced than previously reported after a bolus of 50 µg (10).

Cyclic GMP seems to be not only a marker but also a mediator of ANP



**FIG. 7.** Serum cyclic guanosine monophosphate (C GMP) after a single bolus injection of 200 µg of  $\alpha$ -hANP in volunteers; \* $p < 0.01$ .

activity in vascular smooth muscle cells and endothelial cells (12). *In vitro* the stimulation of cGMP production by ANP seems to be relatively irreversible and the responsiveness to ANP is downregulated by prior exposure to ANP (12). Interestingly, we could not demonstrate any attenuation of plasma cGMP or urinary cGMP excretion after the second of two consecutive  $\alpha$ -hANP bolus injections. After the second bolus, plasma cGMP rose from a still elevated level to an even higher peak concentration (Fig. 8). Correspondingly, urinary cGMP excretion was also higher after the second than after the first  $\alpha$ -hANP bolus. Thus, there seems to be no evidence of a diminished cGMP response after high dose  $\alpha$ -hANP bolus applications at a 30-min interval.

Echocardiography after  $\alpha$ -hANP application revealed significant decreases of ESD which, with EDD remaining unchanged, led to an increase of computed EF after each  $\alpha$ -hANP injection. Also, SV and CI increased after  $\alpha$ -hANP. Similar to the cGMP response, there was no diminution of the echocardiographic effects of the second of two consecutive bolus injections in protocol 2.




FIG. 8. Serum cyclic guanosine monophosphate (cGMP) after repeated bolus injections of 200  $\mu$ g  $\alpha$ -hANP at a 30-min interval; \* $p < 0.01$ .

In healthy volunteers, there seems to be no evidence for a cardiodepressive effect of the drug, which had been reported earlier in animals (13). Instead, the data point toward improved cardiac performance which may, because of reported vasodilating effects of  $\alpha$ -hANP (3), be due to reductions of preload and afterload. Apart from possible direct myocardial effects, temporarily elevated catecholamine levels as a consequence of vasodilatation (14) may contribute to improvement of cardiac performance.

Like others (1,2,4,10), we observed increased diuresis and natriuresis after  $\alpha$ -hANP application in non-salt restricted healthy volunteers. Increases of diuresis and natriuresis in this study were larger than those previously reported after bolus injections, probably because of the higher dose of  $\alpha$ -hANP (1,2,4,10). The recorded renal effects of  $\alpha$ -hANP persisted up to 60 min after a bolus injection, which is remarkably longer than the duration of the cardiovascular effects.

Because of the prolonged renal action of a single dose, the second bolus in protocol 2 was given with an overlap of the renal effect of the first bolus. Nevertheless, there was no attenuation of diuretic and natriuretic effects after the second bolus.

Endogenous plasma  $\alpha$ -hANP is elevated in patients with congestive heart failure and may have regulatory functions (15,16). Studies in small numbers of patients with congestive heart failure showed beneficial effects of  $\alpha$ -hANP due to its vasodilating and diuretic properties. Responses to  $\alpha$ -hANP in those patients has been varying. Although Riegger et al. (17) and Saito et al. (18) observed vasodilatory as well as diuretic effects after bolus injections, Firth (19) found only renal but no cardiovascular effects. After continuous infusion of  $\alpha$ -hANP in patients with heart failure, Mollina et al. (20) observed beneficial effects in cardiovascular and renal parameters, but several others (21-23) could not confirm diuretic effects after  $\alpha$ -hANP infusion.

In the present study, reproducible improvement of cardiac performance and prolonged diuretic effects could be demonstrated in healthy volunteers after single and two consecutive bolus injections of 200  $\mu$ g of  $\alpha$ -hANP. Although conclusions from data obtained in healthy volunteers must be drawn with care, one can speculate that improved cardiac performance together with sustained diuresis and natriuresis after repeated high dose bolus application of  $\alpha$ -hANP might be beneficial in the acute treatment of congestive heart failure.

## CONCLUSIONS

Single and repeated bolus applications of 200  $\mu$ g of  $\alpha$ -hANP in healthy volunteers produces increases of plasma cGMP concentrations and urinary cGMP excretion, diuresis and natriuresis, heart rate and echocardiographically determined ejection fraction, and decreases in arterial blood pressure. Comparing the effects of two consecutive bolus injections of  $\alpha$ -hANP at a 30-minute interval, there was no evidence for attenuation of cGMP response, diuresis, natriuresis, or cardiovascular effects.

## REFERENCES

1. Richards, A. M., Nicholls, M. G., Ikram, H., et al. (1985): Renal, haemodynamic and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. *Lancet*, 545-549.
2. Tikkanen, I., Fyrquist, F., Metsarinne, K., et al. (1985): Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. *Lancet*, 66-69.
3. Bolli, P., Müller, F. B., Linder, L., et al. (1987): The vasodilator potency of atrial natriuretic peptide in man. *Circulation*, 75:221-228.
4. Cuneo, R. C., Espiner, R. A., Nicholls, M. G., et al. (1986): Renal, hemodynamic, and hormonal response to atrial natriuretic peptide infusions in normal man, and effect of sodium intake. *J. Clin. Endocrinol. Metab.*, 63:946-953.

5. Indolfi, C., Piscione, F., Volpe, M., et al. (1988): Effects of atrial natriuretic peptide on left ventricular performance in man. *J. Am. Coll. Cardiol. Suppl.*, I:89A.
6. Waldhäusl, W., Vierhapper, H., and Nowotny, P. (1986): Prolonged administration of human atrial natriuretic peptide in healthy men: Evanescent effects on diuresis and natriuresis. *J. Clin. Endocrinol. Metab.*, 62:956-959.
7. Sahn, D. J., DeMaria, A., Kisslo, J., et al. (1978): Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. *Circulation*, 58:1072-1083.
8. Teichholz, L. E., Kreulen, T., Herman, M. V., et al. (1976): Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy. *Am. J. Cardiol.*, 37:7-11.
9. Quinones, M. A., Pickering, E., and Alexander, J. K. (1978): Percentage of shortening of the echocardiographic left ventricular dimension. *Chest*, 74:59-65.
10. Gerzer, R., Witzgall, H., Tremblay, J., et al. (1985): Rapid increase in plasma and urinary GMP after bolus injection of atrial natriuretic factor in man. *J. Clin. Endocrinol. Metab.*, 61:1217-1219.
11. Winer, B. J. (1971): *Statistical Principles in Experimental Design*, ed. 2. McGraw-Hill, New York.
12. Hamet, P., Tremblay, J., Pang, S. C., et al. (1986): Cyclic GMP as mediator and biological marker of atrial natriuretic factor. *J. Hypertens.*, 4(Suppl. II):49-56.
13. Kleinert, H. D., Volpe, M., Odell, G., et al. (1986): Cardiovascular effects of atrial natriuretic factor in anaesthetized and conscious dogs. *Hypertension*, 8:312-317.
14. Weidman, P., Gnädinger, M. P., Ziswiler, H. R., et al. (1986): Cardiovascular, endocrine and renal effects of atrial natriuretic peptide in essential hypertension. *J. Hypertens.*, 4(Suppl. II):71-83.
15. Dietz, J., Purgaj, J., Lang, R. E., et al. (1986): Pressure dependent release of atrial natriuretic peptide (ANP) in patients with chronic cardiac diseases: Does it reset? *Klin. Wochenschr.*, 64(Suppl. VI):42-46.
16. Burnett, J. C., Kao, P. C., Hu, D. C., et al. (1986): Atrial natriuretic peptide elevation in congestive heart failure in the human. *Science*, 231:1145-1147.
17. Riegger, A. J. G., Kromer, E. P., and Kochsiek, K. (1986): Atrial natriuretic peptide in patients with severe heart failure. *Klin. Wochenschr.*, 64(Suppl. VI):89-92.
18. Saito, H., Ogihara, T., Nakamaru, M., et al. Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure. *Clin. Pharmacol. Ther.*, 42:142-147.
19. Firth, B. G., Perna, R. C., Bellomo, J. F., et al. (1988): Renal and hemodynamic effects of low and high dose ANF bolus doses in congestive heart failure. *J. Am. Coll. Cardiol. Suppl.*, I:118A.
20. Mollina, C. R., Fowler, M. B., McCrory, S., et al. (1988): Pharmacodynamics and pharmacokinetics of atrial natriuretic peptide in severe congestive heart failure. *J. Am. Coll. Cardiol. Suppl.*, I:239A.
21. Crozier, I. G., Nicholls, M. G., Ikram, H., et al. (1986): Hemodynamic effects of atrial peptide infusion in heart failure. *Lancet*, 2:1242-1245.
22. Cody, R. C., Atlas, S. A., Laragh, J. H., et al. (1986): Atrial natriuretic factor in normal subjects and heart failure patients. *J. Clin. Invest.*, 78:1362-1374.
23. Saito, Y., Nakao, K., Nishimura, K., et al. (1987): Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effects on left ventricular function. *Circulation*, 76:115-124.